查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2086196

非小細胞肺癌治療市場：依療法、治療階段、生物標記表達、最終用戶和分銷管道分類－2026-2032年全球市場預測

Non-small Cell Lung Cancer Therapeutics Market by Treatment Type, Line Of Therapy, Biomarker Expression, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，非小細胞肺癌治療市場將成長至 671.3 億美元，複合年成長率為 9.75%。

主要市場統計數據
基準年 2025 349.8億美元
預計年份：2026年 382.6億美元
預測年份 2032 671.3億美元
複合年成長率 (%) 9.75%

非小細胞肺癌（NSCLC）的治療正從廣泛應用的化療轉向基於生物標記、分期特異性且日益個體化的治療策略。 NSCLC約佔肺癌病例的80%至85%，肺癌仍是全球癌症死亡的主要原因之一。國際癌症研究機構（IARC）估計，到2022年，全球將新增約250萬例肺癌病例，並有180萬人死於肺癌。

免疫查核點抑制劑、針對可治療基因突變的標靶治療、抗體藥物複合體(ADC) 以及將全身性治療延伸至疾病早期階段的手術全期手術期方案的臨床價值，共同塑造了這個市場。隨著 EGFR、ALK、ROS1、BRAF、MET、RET、NTRK、HER2 和 KRAS 等基因突變檢測在治療選擇中發揮核心作用，製藥、診斷和醫療服務提供者之間的生態系統正透過精準腫瘤學工作流程變得日益緊密地聯繫在一起。

非小細胞肺癌（NSCLC）治療格局的變革性變化

非小細胞肺癌（NSCLC）的治療格局正在經歷結構性變革，免疫療法和標靶治療正在重新定義轉移性、輔助性治療和新輔助治療的標準。 PD-1、PD-L1 和 CTLA-4 路徑抑制劑正在拓展以生存為導向的治療選擇，而標靶治療則在生物標記定義的患者群體中取得了顯著的臨床療效，這些患者群體包括攜帶 EGFR 突變、ALK 陽性、ROS1 陽性、RET 陽性、MET 14 號外顯子突變、BRAF GNTD、DHERE突變 GNT12 NSC NSC N​​OD.患者。

人工智慧對非小細胞肺癌（NSCLC）治療的累積影響

人工智慧（AI）並非簡單地取代臨床專家，而是正在成為非小細胞肺癌（NSCLC）整體治療的基礎。 AI驅動的放射學、病理影像分析、臨床試驗配對工具和真實世界數據（RWE）平台能夠加速患者識別，提高營運效率，並增強對複雜臨床和分子數據解讀的一致性。

全球非小細胞肺癌 (NSCLC) 治療的關鍵區域見解

在北美，非小細胞肺癌的治療受益於完善的腫瘤學基礎設施、廣泛應用的次世代定序、高密度的臨床試驗以及已通過核准的免疫療法和標靶治療的快速發展。儘管美國仍然是全球生物標記主導藥物研發的中心，但加拿大的公共醫療保險報銷體系更注重醫療技術評估、實際價值以及各省之間的公平醫療服務取得。

關於非小細胞肺癌治療的關鍵群體特異性見解

在東協地區，非小細胞肺癌（NSCLC）治療的需求受到以下因素的影響：癌症治療投入的增加、私人癌症治療網路的擴張，以及各國獲得全面基因組分析的機會不均。新加坡、泰國、馬來西亞、印尼、越南和菲律賓的醫保報銷體系和基礎設施各不相同，因此，夥伴關係模式和減輕診斷的經濟負擔對於市場發展至關重要。

各國非小細胞肺癌治療的關鍵見解

美國在非小細胞肺癌（NSCLC）治療創新方面處於領先地位，這得益於監管部門的批准、主要癌症中心生物標記檢測的高普及率以及廣泛的臨床試驗網路。加拿大強調實證報銷和省級准入途徑，而墨西哥和巴西正在擴展其腫瘤治療體系，但公立和私立醫療體系之間的醫療服務取得仍然存在差距。

為行業領導者提供的實用建議

產業領導者應將獲取生物標記視為一項商業性和臨床上的必要條件，並優先考慮其可行性。投資於伴隨診斷、反射性檢測和液態生物檢體的普及，並與病理網路建立合作關係，可以減少治療延誤，並提高標靶治療治療和免疫腫瘤療法適用患者的識別率。

非小細胞肺癌（NSCLC）治療藥物的分析調查方法

本執行摘要採用以公開可查且檢驗的資訊來源為依據的二手主導方法編寫，資料來源包括監管公告、腫瘤學指南、同行評審文獻、癌症檢驗資料、臨床試驗資料庫和全球衛生統計資料。重點關注已驗證的流行病學數據、已通過核准的治療分類、已確立的生物標記以及已記錄的區域可及性。

結論：非小細胞肺癌（NSCLC）治療的未來

非小細胞肺癌（NSCLC）治療市場正進入一個更成熟的階段，其特徵是精準醫療、免疫療法的整合、早期干預以及人工智慧驅動的診療路徑。儘管科學進步拓展了治療選擇，但治療效果越來越依賴及時診斷、全面的生物標記檢測、合理的治療順序以及公平的醫療資源取得。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 非小細胞肺癌治療市場：依治療方法分類

  • 化療
  • 免疫療法
    • CTLA-4抑制劑
    • PD-1抑制劑
      • Nivolumab
      • Pembrolizumab
    • PD-L1抑制劑
      • Atezolizumab
      • Avelumab
      • Durvalumab
  • 標靶治療
    • ALK抑制劑
    • BRAF抑制劑
    • EGFR抑制劑
    • ROS1抑制劑

第8章 非小細胞肺癌治療市場：依治療階段分類

  • 第 1 行
    • 化療
    • 聯合治療
    • 免疫療法
    • 標靶治療
  • 第二行
    • 化療
    • 聯合治療
    • 免疫療法
    • 標靶治療
  • 從第三行開始
    • 化療
    • 聯合治療
    • 免疫療法
    • 標靶治療

第9章 非小細胞肺癌治療市場：依生物標記表達分類

  • ALK 重構
  • EGFR 變異體
  • PD-L1高表達
  • KRAS變異

第10章 非小細胞肺癌治療市場：依最終用戶分類

  • 醫院
  • 腫瘤診所
  • 門診手術中心
  • 專科癌症中心

第11章 非小細胞肺癌治療市場：依分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章 非小細胞肺癌治療市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章 非小細胞肺癌治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 非小細胞肺癌治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • AbbVie Inc.
  • Akeso, Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BeiGene, Ltd.
  • Blueprint Medicines Corporation
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Cullinan Therapeutics, Inc.
  • Daiichi Sankyo Company, Limited
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Exelixis, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GSK plc
  • Incyte Corporation
  • Innovent Biologics, Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Novocure GmbH
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
  • Summit Therapeutics Inc.
  • Takeda Pharmaceutical Company Limited
  • Zai Lab Limited
Product Code: MRR-036C5CF3B524

The Non-small Cell Lung Cancer Therapeutics Market is projected to grow by USD 67.13 billion at a CAGR of 9.75% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 34.98 billion
Estimated Year [2026] USD 38.26 billion
Forecast Year [2032] USD 67.13 billion
CAGR (%) 9.75%

Non-small cell lung cancer (NSCLC) therapeutics are moving from broadly applied chemotherapy toward biomarker-led, stage-specific, and increasingly individualized treatment strategies. NSCLC accounts for approximately 80% to 85% of lung cancer cases, and lung cancer remains the leading cause of cancer death globally, with the International Agency for Research on Cancer estimating about 2.5 million new lung cancer cases and 1.8 million deaths in 2022.

The market is shaped by the clinical value of immune checkpoint inhibitors, targeted therapies for actionable alterations, antibody-drug conjugates, and perioperative regimens that extend systemic treatment into earlier-stage disease. As testing for EGFR, ALK, ROS1, BRAF, MET, RET, NTRK, HER2, and KRAS alterations becomes central to treatment selection, pharmaceutical, diagnostic, and provider ecosystems are increasingly linked through precision oncology workflows.

Transformative Shifts in the NSCLC Treatment Landscape

The NSCLC treatment landscape is undergoing structural change as immunotherapy and targeted therapy redefine standards of care across metastatic, adjuvant, and neoadjuvant settings. PD-1, PD-L1, and CTLA-4 pathway inhibitors have expanded survival-oriented treatment options, while targeted agents have produced clinically meaningful outcomes in biomarker-defined populations such as EGFR-mutated, ALK-positive, ROS1-positive, RET-positive, MET exon 14, BRAF V600E, NTRK fusion, HER2-altered, and KRAS G12C NSCLC.

A major transformation is the shift from single-line treatment thinking to lifecycle-based disease management. Molecular testing at diagnosis, minimal residual disease assessment, liquid biopsy adoption, and resistance-mechanism profiling are supporting more adaptive therapy selection. Regulatory approvals in resectable NSCLC have also changed commercial strategy by increasing focus on earlier intervention, multidisciplinary care coordination, and evidence generation beyond late-stage disease.

Cumulative Impact of Artificial Intelligence on NSCLC Therapeutics

Artificial intelligence is becoming an enabling layer across NSCLC therapeutics rather than a standalone replacement for clinical expertise. AI-supported radiology, pathology image analysis, trial-matching tools, and real-world evidence platforms can accelerate patient identification, improve operational efficiency, and support more consistent interpretation of complex clinical and molecular data.

The cumulative impact is most visible in precision oncology execution. AI can help identify suspicious lung nodules from imaging, prioritize cases for review, extract unstructured electronic health record data, and match patients to biomarker-driven trials. In drug development, machine learning is being applied to target discovery, synthetic control arms, pharmacovigilance signal detection, and patient stratification; however, clinical adoption depends on validation, regulatory oversight, data quality, interoperability, and protection against algorithmic bias.

Key Regional Insights Across Global NSCLC Therapeutics

In North America, NSCLC therapeutics benefit from advanced oncology infrastructure, broad access to next-generation sequencing, high clinical trial density, and rapid uptake of approved immunotherapies and targeted agents. The United States remains a global anchor for biomarker-driven drug development, while Canada's public reimbursement environment emphasizes health technology assessment, real-world value, and equitable access across provinces.

Europe demonstrates strong adoption of guideline-based care through national health systems, cancer networks, and European regulatory pathways, although reimbursement timing differs by country. Asia-Pacific is highly consequential because of disease burden and distinct molecular epidemiology, particularly the higher prevalence of EGFR-mutated NSCLC reported in many East Asian populations compared with Western populations. China, Japan, South Korea, Australia, and India are expanding precision oncology capacity, trial participation, and domestic innovation.

Latin America shows growing demand for immuno-oncology and molecular diagnostics, but access is uneven due to reimbursement gaps and laboratory infrastructure differences. The Middle East, led by Gulf markets, is investing in oncology centers, genomic medicine programs, and specialty care capacity. Africa remains underpenetrated for advanced NSCLC therapeutics, with priorities centered on earlier diagnosis, pathology capacity, access to essential cancer medicines, and scalable diagnostic partnerships.

Key Group Insights for NSCLC Therapeutics

Within ASEAN, NSCLC therapeutics demand is shaped by rising cancer care investment, expanding private oncology networks, and uneven access to comprehensive genomic profiling across countries. Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines present different reimbursement and infrastructure profiles, making partnership models and diagnostic affordability central to market development.

The GCC is advancing oncology through national transformation programs, specialized cancer centers, and investments in genomic medicine, supporting faster adoption of premium immunotherapies and targeted treatments in selected markets. The European Union provides a large, regulated environment where centralized authorization, health technology assessment reform, and cross-border clinical research influence access and evidence expectations. BRICS countries represent a major volume and innovation opportunity, especially as China, India, and Brazil expand local manufacturing, clinical trials, and precision oncology pathways.

G7 markets set many global benchmarks for clinical evidence, reimbursement negotiation, pharmacovigilance, and guideline adoption. NATO member countries overlap substantially with advanced Western oncology markets, where security of pharmaceutical supply chains, clinical research resilience, and health system readiness have become strategic considerations for high-value oncology therapeutics.

Key Country Insights in NSCLC Therapeutics

The United States leads NSCLC therapeutic innovation through regulatory approvals, high biomarker testing penetration in major cancer centers, and extensive clinical trial networks. Canada emphasizes evidence-based reimbursement and provincial access pathways, while Mexico and Brazil are expanding oncology capabilities but continue to face access variability between public and private systems.

In Europe, the United Kingdom relies on health technology assessments and national care pathways, Germany supports early access after European approval while benefit assessment shapes pricing, and France maintains strong oncology networks and reimbursement evaluation. Italy and Spain show broad specialist expertise with regional access differences, while Russia's NSCLC environment is affected by domestic policy, procurement dynamics, and constrained access to some global innovations.

China is one of the most important NSCLC countries due to patient volume, high clinical trial activity, domestic biopharmaceutical development, and expanding reimbursement coverage for selected innovative drugs. India combines a large disease burden with affordability constraints and growing molecular diagnostics adoption. Japan and South Korea are advanced precision oncology markets with strong uptake of targeted therapies, while Australia benefits from structured reimbursement, national cancer strategies, and high-quality oncology care infrastructure.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize biomarker access as a commercial and clinical imperative. Investments in companion diagnostics, reflex testing, liquid biopsy availability, and partnerships with pathology networks can reduce treatment delays and improve eligible patient identification for targeted therapies and immuno-oncology regimens.

Organizations should also design evidence strategies that address payer scrutiny across overall survival, progression-free survival, quality of life, treatment sequencing, and real-world effectiveness. Differentiation will increasingly depend on performance in defined subpopulations, tolerability, convenience, central nervous system activity, and resistance management.

Actionable priorities include expanding trial diversity, building region-specific access models, strengthening pharmacovigilance, integrating AI-enabled patient-finding tools responsibly, and preparing for combination therapy economics. Leaders that align therapeutic innovation with diagnostic readiness and reimbursement evidence will be better positioned in the evolving NSCLC therapeutics market.

Research Methodology for NSCLC Therapeutics Analysis

This executive summary is developed through a secondary research-led methodology using publicly available, verifiable sources, including regulatory agency communications, oncology guidelines, peer-reviewed literature, cancer registry data, clinical trial databases, and global health statistics. Emphasis is placed on validated epidemiology, approved therapeutic classes, established biomarkers, and documented regional access patterns.

Insights are synthesized through triangulation across clinical, regulatory, commercial, and healthcare-delivery evidence. The methodology prioritizes data integrity, avoids unsupported market claims, and distinguishes established clinical adoption from emerging opportunities. Where regional or country trends vary, interpretation is grounded in observable healthcare infrastructure, reimbursement systems, diagnostic capacity, and clinical research activity.

Conclusion: The Future of NSCLC Therapeutics

The NSCLC therapeutics market is entering a more sophisticated phase defined by precision medicine, immunotherapy integration, earlier-stage intervention, and AI-enabled care pathways. Scientific progress has expanded treatment options, but outcomes increasingly depend on timely diagnosis, comprehensive biomarker testing, therapy sequencing, and equitable access.

Organizations that connect drug development with diagnostics, real-world evidence, regional reimbursement strategies, and responsible digital innovation will be best positioned to create durable value. As NSCLC care continues to evolve, the most competitive stakeholders will be those that improve both therapeutic efficacy and the practical delivery of precision oncology at scale.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Non-small Cell Lung Cancer Therapeutics Market, by Treatment Type

  • 7.1. Chemotherapy
  • 7.2. Immunotherapy
    • 7.2.1. CTLA-4 Inhibitors
    • 7.2.2. PD-1 Inhibitors
      • 7.2.2.1. Nivolumab
      • 7.2.2.2. Pembrolizumab
    • 7.2.3. PD-L1 Inhibitors
      • 7.2.3.1. Atezolizumab
      • 7.2.3.2. Avelumab
      • 7.2.3.3. Durvalumab
  • 7.3. Targeted Therapy
    • 7.3.1. ALK Inhibitors
    • 7.3.2. BRAF Inhibitors
    • 7.3.3. EGFR Inhibitors
    • 7.3.4. ROS1 Inhibitors

8. Non-small Cell Lung Cancer Therapeutics Market, by Line Of Therapy

  • 8.1. First Line
    • 8.1.1. Chemotherapy
    • 8.1.2. Combination Therapy
    • 8.1.3. Immunotherapy
    • 8.1.4. Targeted Therapy
  • 8.2. Second Line
    • 8.2.1. Chemotherapy
    • 8.2.2. Combination Therapy
    • 8.2.3. Immunotherapy
    • 8.2.4. Targeted Therapy
  • 8.3. Third Or Later
    • 8.3.1. Chemotherapy
    • 8.3.2. Combination Therapy
    • 8.3.3. Immunotherapy
    • 8.3.4. Targeted Therapy

9. Non-small Cell Lung Cancer Therapeutics Market, by Biomarker Expression

  • 9.1. ALK Rearrangement
  • 9.2. EGFR Mutant
  • 9.3. High PD-L1 Expression
  • 9.4. KRAS Mutant

10. Non-small Cell Lung Cancer Therapeutics Market, by End User

  • 10.1. Hospitals
  • 10.2. Oncology Clinics
  • 10.3. Ambulatory Surgical Centers
  • 10.4. Specialty Cancer Centers

11. Non-small Cell Lung Cancer Therapeutics Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Non-small Cell Lung Cancer Therapeutics Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Non-small Cell Lung Cancer Therapeutics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Non-small Cell Lung Cancer Therapeutics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Concentration Analysis, 2025
    • 15.1.1. Concentration Ratio (CR)
    • 15.1.2. Herfindahl Hirschman Index (HHI)
  • 15.2. Recent Developments & Impact Analysis, 2025
  • 15.3. Product Portfolio Analysis, 2025
  • 15.4. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. AbbVie Inc.
  • 16.2. Akeso, Inc.
  • 16.3. Amgen Inc.
  • 16.4. Astellas Pharma Inc.
  • 16.5. AstraZeneca PLC
  • 16.6. Bayer AG
  • 16.7. BeiGene, Ltd.
  • 16.8. Blueprint Medicines Corporation
  • 16.9. Boehringer Ingelheim International GmbH
  • 16.10. Bristol-Myers Squibb Company
  • 16.11. Cullinan Therapeutics, Inc.
  • 16.12. Daiichi Sankyo Company, Limited
  • 16.13. Eisai Co., Ltd.
  • 16.14. Eli Lilly and Company
  • 16.15. Exelixis, Inc.
  • 16.16. F. Hoffmann-La Roche Ltd.
  • 16.17. Gilead Sciences, Inc.
  • 16.18. GSK plc
  • 16.19. Incyte Corporation
  • 16.20. Innovent Biologics, Inc.
  • 16.21. Johnson & Johnson
  • 16.22. Merck & Co., Inc.
  • 16.23. Novartis AG
  • 16.24. Novocure GmbH
  • 16.25. Pfizer Inc.
  • 16.26. Regeneron Pharmaceuticals, Inc.
  • 16.27. Sanofi S.A.
  • 16.28. Summit Therapeutics Inc.
  • 16.29. Takeda Pharmaceutical Company Limited
  • 16.30. Zai Lab Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CHEMOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CHEMOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CHEMOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CTLA-4 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CTLA-4 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CTLA-4 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PD-1 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PD-1 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PD-1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NIVOLUMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NIVOLUMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NIVOLUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PEMBROLIZUMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PEMBROLIZUMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PEMBROLIZUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PD-L1 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PD-L1 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ATEZOLIZUMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ATEZOLIZUMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ATEZOLIZUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL AVELUMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL AVELUMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL AVELUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DURVALUMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DURVALUMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DURVALUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL TARGETED THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL TARGETED THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ALK INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ALK INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ALK INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BRAF INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BRAF INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BRAF INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL EGFR INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL EGFR INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL EGFR INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ROS1 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ROS1 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ROS1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL FIRST LINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL FIRST LINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL FIRST LINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CHEMOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CHEMOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CHEMOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL COMBINATION THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL COMBINATION THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL TARGETED THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL TARGETED THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL SECOND LINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL SECOND LINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL SECOND LINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CHEMOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CHEMOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CHEMOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL COMBINATION THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL COMBINATION THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL TARGETED THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL TARGETED THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL THIRD OR LATER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL THIRD OR LATER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL THIRD OR LATER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CHEMOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CHEMOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CHEMOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL COMBINATION THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL COMBINATION THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL TARGETED THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL TARGETED THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ALK REARRANGEMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ALK REARRANGEMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ALK REARRANGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL EGFR MUTANT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL EGFR MUTANT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL EGFR MUTANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL HIGH PD-L1 EXPRESSION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL HIGH PD-L1 EXPRESSION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL HIGH PD-L1 EXPRESSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL KRAS MUTANT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL KRAS MUTANT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL KRAS MUTANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL ONCOLOGY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL ONCOLOGY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL ONCOLOGY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL SPECIALTY CANCER CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL SPECIALTY CANCER CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL SPECIALTY CANCER CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2018-2032 (USD MILLION)
  • TABLE 221. ASEAN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 223. GCC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 224. GCC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. GCC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 226. GCC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 227. GCC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 228. GCC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 229. GCC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 230. GCC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 231. GCC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
  • TABLE 232. GCC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, 2018-2032 (USD MILLION)
  • TABLE 233. GCC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2018-2032 (USD MILLION)
  • TABLE 234. GCC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. GCC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPEAN UNION NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. BRICS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 252. BRICS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 253. BRICS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 254. BRICS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2018-2032 (USD MILLION)
  • TABLE 260. BRICS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 261. BRICS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 262. G7 NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 263. G7 NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. G7 NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 265. G7 NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 266. G7 NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 267. G7 NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 268. G7 NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 269. G7 NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 270. G7 NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
  • TABLE 271. G7 NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, 2018-2032 (USD MILLION)
  • TABLE 272. G7 NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2018-2032 (USD MILLION)
  • TABLE 273. G7 NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 274. G7 NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 275. NATO NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 276. NATO NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 277. NATO NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 278. NATO NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 279. NATO NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 280. NATO NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 281. NATO NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 282. NATO NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 283. NATO NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
  • TABLE 284. NATO NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, 2018-2032 (USD MILLION)
  • TABLE 285. NATO NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2018-2032 (USD MILLION)
  • TABLE 286. NATO NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 287. NATO NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 288. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 289. UNITED STATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 290. UNITED STATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. UNITED STATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 292. UNITED STATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 293. UNITED STATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 294. UNITED STATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 295. UNITED STATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 296. UNITED STATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 297. UNITED STATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
  • TABLE 298. UNITED STATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, 2018-2032 (USD MILLION)
  • TABLE 299. UNITED STATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2018-2032 (USD MILLION)
  • TABLE 300. UNITED STATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 301. UNITED STATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 302. CANADA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 303. CANADA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 304. CANADA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 305. CANADA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 306. CANADA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 307. CANADA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 308. CANADA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 309. CANADA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 310. CANADA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2032 (USD MILLION)
  • TABLE 311. CANADA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, 2018-2032 (USD MILLION)
  • TABLE 312. CANADA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2018-2032 (USD MILLION)
  • TABLE 313. CANADA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 314. CANADA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 315. MEXICO NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 316. MEXICO NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 317. MEXICO NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 318. MEXICO NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 319. MEXICO NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 320. MEXICO NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 321. MEXICO NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 322. MEXICO NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2032 (USD MILLION)
  • TABLE 323. MEXICO NON-SMALL CELL LUNG C